RxDoctor Payments DataLook up a doctor →

Charles Lin, MD

Clinical Cardiac Electrophysiology · Bowling Green, KYNPI 1326042185

Payments from drug & device makers

$19,073in general payments, 2019–2025

Across 411 payments — averaging $46.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$11K
  • Medtronic$1K
  • Novartis$845
  • Pfizer$831
  • AstraZeneca$650
  • Amgen$450
  • plus $3K from 31 others

What the payments were for

  • Speaking & faculty fees$10,03053%
  • Travel & lodging$1,6339%
  • Food & beverage$7,26938%
  • Education$1411%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,073 in reported general payments places this provider in the 35th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

See all clinical cardiac electrophysiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$404,853
Medicare patients
697
Services billed
9,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban801$691,017
EntrestoSacubitril/Valsartan654$609,606
FarxigaDapagliflozin Propanediol625$480,863
JardianceEmpagliflozin187$155,348
BrilintaTicagrelor192$133,714
XareltoRivaroxaban159$117,316
Repatha SureclickEvolocumab180$115,027
OzempicSemaglutide62$99,667
MultaqDronedarone Hcl67$71,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$50,401
KerendiaFinerenone57$46,138
VascepaIcosapent Ethyl79$37,989
DapagliflozinDapagliflozin Propanediol49$23,653
Ranolazine ErRanolazine181$18,977
LokelmaSodium Zirconium Cyclosilicate12$15,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$831$691,017801 claims
AstraZenecaFarxiga, Brilinta, Lokelma$650$630,272829 claims
NovartisEntresto$845$609,606654 claims
Boehringer IngelheimJardiance, Spiriva Respimat$267$165,277206 claims
Johnson & JohnsonXarelto$377$117,316159 claims
Novo NordiskOzempic$232$99,66762 claims
Sanofi-aventis U.S. LLCMultaq$181$71,41967 claims
BayerKerendia$44$46,13857 claims
Kowa Pharmaceuticals America, Inc.Bystolic$237$2,06612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

Other clinical cardiac electrophysiology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →